Immunome (IMNM) Stock Forecast & Price Target

Immunome is attractive because its lead programs pair clear near-term clinical catalysts with differentiated biology: varegacestat produced an 84% reduction in progression or death risk, a 56% confirmed ORR versus 9% for placebo, and improved pain, while IM-1021 has already shown objective responses across multiple dose levels. The bullish case is further strengthened by a platform thesis, since HC74’s low-efflux, high-permeability design and DAR of 8 could help IM-1021 overcome prior ROR1 ADC limitations, especially in heavily pretreated lymphoma and potentially beyond. With $520MM in cash at 2Q26 funding operations into 2028, plus first-patient dosing in IM-1617 and IM-3050 and upcoming INDs for IM-1340 and IM-1335, the company has both balance-sheet runway and multiple shots on goal.

Immunome is facing a fundamental translational risk in ROR1-directed programs because high mRNA expression does not reliably translate into actionable surface antigen density in solid tumors, and the literature shows conflicting IHC and surface-expression findings across the same cancer types. That uncertainty undermines biomarker selection and raises the chance of antigen escape, especially since ROR1 appears non-essential for cancer cell survival and Broad Institute DepMap data across 1,200+ cell lines show knockout has little effect on growth. The weak solid-tumor experience with zilovertamab vedotin, where roughly one responder emerged out of 100+ participants, reinforces a bearish view that the platform may struggle to generate durable efficacy outside lymphoma-like settings.